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Introduction 
During the last 10 years the European medicines Agency (EMA) organised a number of workshops on 
modelling and simulation, working towards greater integration of modelling and simulation (M&S) in 
the development and regulatory assessment of medicines. In the 2011 EMA - European Federation of 
Pharmaceutical Industries and Associations (EFPIA) workshop on Modelling and Simulation European 
regulators agreed to the necessity to build to expertise be able to review M&S data provided by 
companies in their dossier. This lead to the establishment of the EMA modelling and simulation working 
group (MSWG). Also there was agreement reached on the need for harmonisation on good M&S 
practices and for continuing dialogue across all parties. The MSWG acknowledges the initiative of the 
EFPIA Model-Informed Drug Discovery and Development (MID3) group in promoting greater 
consistency in practice, application and documentation of M&S and considers the paper is an important 
contribution towards achieving this objective. 
 
Main Commentary 
What the MSWG perceives as a problem with the current applications of M&S is that they are often 
dissociated from clinical decisions on the design and objectives of clinical trials. Although in areas like 
paediatric drug development and dose selection the M&S, the clinical and the statistical objectives are 
all considered and taken into account in study design and analysis, these are otherwise often seen as 
standalone applications and reported as such. This ad-hoc application of M&S has implications on the 
strength of evidence supporting modelling assumptions and consequently may limit the weight of M&S 
in the clinical and regulatory decision making. For instance, sometimes M&S analyses are not well 
integrated into a phase 3 study protocol since the rationale behind it has not been fully communicated 
and understood. Then the collection of the data may become suboptimal and it will be hard to answer 
questions about the influence of intrinsic or extrinsic factors on exposure and response in patients. A 
better alternative is to clearly motivate the analysis, set up objectives that are relevant and 
understandable to the whole development team and to plan the study and analyses accordingly. 
 
A key element in the MID3 white paper
1 is the implementation strategy, i.e., a strategic plan which closely follows the drug development 
steps and lays out the knowledge gaps, the important questions and how these should be addressed 
through model-informed activities across compound, mechanism and disease level. The development 
of a strategic plan, as proposed by the MID3 group is expected to improve communication between the 
different scientific disciplines involved in drug discovery and development and optimize utilization of 
quantitative tools and study designs. The MSWG considers that the regulatory review of models as part 
of Scientific Advice, Paediatric Investigation Plan (PIP), Marketing Authorisation Application (MAA) and 
other submissions would be very much facilitated by having access to the MID3 strategic plan. 
 
Another proposal included in the MID3 paper that is important is the documentation of assumptions, 
how they are assessed and what impact they have on decisions. The MSWG sometimes finds it 
challenging to discuss models with other disciplines. The modelers are often not well informed to 
evaluate the clinical assumptions included in the models. On the other hand the clinicians often 
struggle to understand the mathematical language describing the clinical assumptions and the clinical 
impact of the data/mathematical/statistical assumptions. This creates a communication gap and 
unnecessarily prolongs the integrated discussion needed about how the drug product should be 
developed and utilized in the best way. 
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In the best case the modelling assumptions can be assessed by model diagnostics, sensitivity tests or 
plain reasoning. If this is the case, some level of reassurance can be provided on the model predictions 
and inferences. If not, the uncertainty on the assumptions adds to the overall model uncertainty. In 
the end, for those using models in the context of drug development and evaluation it is important to 
manage uncertainties by evaluating their clinical consequences/impact. The assumptions table 
provided in the MID3 paper provides a good way to document assumptions, uncertainties and impact 
in regulatory submissions. Such a structured approach is expected to improve the dialogue between 
clinicians, modelers and other disciplines. 
 
Another important way to improve communication between different disciplines is the recommendation 
on the different sections of the analysis report. The targeted approach of sections according to 
audience (all readers vs. technical) is very much welcome.  
 
The MID3 paper includes additional comments on practical aspects of conduct, documentation and 
reporting of modelling and simulation. The proposals, which will not be elaborated here for the sake of 
brevity, are recognised by the MSWG and are clearly an improvement compared to what is currently 
seen in submissions.  
 
The MSWG also notes that in the past few years the abundance and the quality (in terms of context of 
use, adherence to good practices and reporting) of M&S in the submissions have increased. There has 
also been an increased focus on the development of good practice documents pertaining to modelling 
and simulation (Byon et al 20132; Dykstra et al,20153; Overgaard et al, 20154; Nguyen et al5, 2016, 
Jones et al., 20156) from specific companies and industry groups (EFPIA) and professional bodies 
(ISOP, PSI SIGG); the list is not exhaustive. In addition, the interplay between modelers and 
statisticians (i.e., EMA extrapolation workshop7, EMA small population workshop8, ASA-ISOP statistic 
and pharmacometrics interest group) is gaining momentum. The MSWG finds these trends 
encouraging, in the sense that it is indicative that M&S is becoming more integrated within drug 
development. Common themes across all these initiatives are the improvements in communication and 
reporting. There is a desire from MSWG to keep the interaction ongoing with the MID3 EFPIA group, to 
initiate bilateral contacts with other groups developing good practices, and to act as a facilitator for 
further development and regulatory implementation of good modelling practice in general. Through its 
interaction9 with the US FDA OCP pharmacometrics group, PMDA and Health Canada, the MSWG also 
envisages harmonization of good modelling practices across regulators. 
 
To conclude, the MSWG considers the MID3 white paper can potentiate the utility of modelling and 
simulation in regulatory review in moving from an ad-hoc problem solving exercise, as often perceived, 
to an important source of evidence generation that influences development and benefit risk decisions, 
labeling, risk management and is crucial for the product lifecycle. The MSWG supports the principles 
included in the paper and invites other groups developing good practices documents to actively engage 
in discussions with regulators. 
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